Highlights XORTX Therapeutics Inc.

Equities

XRTX

CA98420Q3061

Market Closed - Toronto S.E. Other stock markets 11:03:36 09/05/2024 pm IST			5-day change	1st Jan Change
3.57 ^CAD	-4.80%		+5.00%	+23.10%

22/04	XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal	MT
22/04	XORTX Announces Publication of Key Research in ADPKD	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal	22/04	MT
XORTX Announces Publication of Key Research in ADPKD	22/04	CI
XORTX Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03/04	CI
XORTX Therapeutics Brief: Has Highlighted "Achievements" of 2023 and Preparations for Registration Clinical Trial	19/03	MT
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease	03/01	MT
XORTX Therapeutics Inc. Submits New Patent for the Treatment of Chronic Kidney Disease	03/01	CI
Correction: -- XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease	03/01	MT
XORTX Therapeutics Says Met Nasdaq Continued Listing Requirements	29/11	MT
XORTX Therapeutics Brief: Says Met Nasdaq Continued Listing Requirements	29/11	MT
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
XORTX Therapeutics Brief: Shares expected to begin trading on a post-consolidation basis on the TSX Venture Exchange and the Nasdaq Capital Market when markets open on or about Tuesday, November 14, 2023	10/11	MT
XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting	02/11	CI
XORTX Therapeutics Announced Rescheduling of Special Meeting of Shareholders	25/23/25	MT
XORTX Therapeutics Brief: Announced Rescheduling of Special Meeting of Shareholders	25/23/25	MT
XORTX Reporting that Independent Proxy Firm, ISS, Recommends Shareholders Vote for Share Consolidation Resolution	12/23/12	MT
XORTX Submits Orphan Drug Designation Application to European Medicines Agency to Treat Progressive Kidney Disease	29/23/29	MT
XORTX Therapeutics Brief: Submitting Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease	29/23/29	MT
Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease	29/23/29	CI
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Refile: XORTX Therapeutics Down More Than 4% After Announces PKD Presentation	06/23/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights XORTX Therapeutics Inc.

Equities

XRTX

CA98420Q3061

Highlights

Filters